Congratulations to Co-Founder and Managing Partner Thomas Goss and his coauthors on the recent publication of their payer budget impact study demonstrating the cost savings associated with the use of the Leva Pelvic Health System compared to real-world clinical practice. The study was published in the Journal of Medical Economics and confirms that treatment with the Leva Pelvic Health System, not only delivers better patient outcomes – but results in significant cost savings for health plans. In a United States commercial health plan with 1 million members, the total estimated 24-month cost per treated patient was $10,447 with Leva versus $11,267 with real-world clinical practice, demonstrating a total projected savings of over $25.7 million, or $1.07 PMPM.
See the press release here: Press Release
Link to the article here: Full Article
This analysis confirms that Leva offers not only a highly effective first-line treatment for female urinary incontinence, but also results in a meaningful cost savings for health plans.
